ArticleFrontiers in oncology2026
Case Report: Experience of a rare case of primary acute mast cell leukemia with FGFR1 gene rearrangement.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mast cell leukemia represents the most malignant subtype of systemic mastocytosis, characterized by a dire clinical prognosis. Currently, no standard treatment regimen exists, with allogeneic hematopoietic stem cell transplantation being the sole option that may extend patient survival. Most mastocytosis patients exhibit mutations in the KIT gene. This paper presents a case of mast cell leukemia manifesting primarily as intractable shock and extensive bone destruction. Notably, the patient tested negative for KIT gene mutations but exhibited an FGFR1 gene rearrangement. Initial treatment with venetoclax and azacitidine proved ineffective, prompting a shift to second-line targeted therapy using an FGFR1 inhibitor. This case is the first to report FGFR1 gene rearrangement in a mast cell leukemia patient, offering deeper molecular insights into this highly aggressive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.